Nikolai Kley

Nikolai Kley

Company: Orionis Biosciences LLC

Job title: Founder & Chief Executive Officer


Using Modified Cytokines to Target Immune Receptors for Selective Response Towards Cancer 5:15 pm

Designing modified cytokines that have low affinity/activity towards their natural receptors How to use induced proximity to restore/drive interactions between the modified cytokine and its natural receptor(s) Optimizing selectivity/pharmacology of the modified cytokine by focusing on localizing activity to clinically relevant targets for alleviating diseaseRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.